Analysts Set Expectations for ORKA FY2028 Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Stock analysts at Leerink Partnrs issued their FY2028 EPS estimates for shares of Oruka Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger expects that the company will earn ($2.92) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($1.69) per share.

Other research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Thursday, October 31st. Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 target price on the stock. Wedbush assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price objective on the stock. Lifesci Capital started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $24.04 on Friday. The stock’s 50-day moving average is $26.76. The firm has a market cap of $29.09 million, a price-to-earnings ratio of -3.84 and a beta of 0.87. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of ORKA. FMR LLC bought a new stake in Oruka Therapeutics during the 3rd quarter valued at $114,763,000. RTW Investments LP purchased a new stake in Oruka Therapeutics during the 3rd quarter worth about $45,359,000. Braidwell LP bought a new position in Oruka Therapeutics in the 3rd quarter worth about $12,640,000. Great Point Partners LLC purchased a new position in Oruka Therapeutics during the 3rd quarter valued at about $12,614,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Oruka Therapeutics during the third quarter valued at about $11,822,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.